Quarterly report pursuant to Section 13 or 15(d)

CONCENTRATIONS

CONCENTRATIONS	3 Months Ended
Mar. 31, 2018
Notes to Financial Statements
NOTE 15 - CONCENTRATIONS	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. The Company’s revenues earned from sale of products and services for the three months ended March 31, 2018 included 14%, 23% and 13% (aggregate of 50%) from three customers of the Company’s total revenues. The Company's revenues earned from sale of products and services for the three months ended March 31, 2017 included 12%, 15% and 16% (aggregate of 43%) from three customers of the Company's total revenues. Four customers accounted for 13%, 25%, 11% and 28% (aggregate of 77%) of the Company’s total accounts receivable at March 31, 2018 and three customers accounted for 12%, 19% and 13% (aggregate of 44%) of the Company’s total accounts receivable at December 31, 2017. The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.

CONCENTRATIONS

3 Months Ended

Mar. 31, 2018

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

The Company’s revenues earned from sale of products and services for the three months ended March 31, 2018 included 14%, 23% and 13% (aggregate of 50%) from three customers of the Company’s total revenues.

The Company's revenues earned from sale of products and services for the three months ended March 31, 2017 included 12%, 15% and 16% (aggregate of 43%) from three customers of the Company's total revenues.

Four customers accounted for 13%, 25%, 11% and 28% (aggregate of 77%) of the Company’s total accounts receivable at March 31, 2018 and three customers accounted for 12%, 19% and 13% (aggregate of 44%) of the Company’s total accounts receivable at December 31, 2017.

The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.